Poor market reaction to another commercial deal but I guess not...

Poor market reaction to another commercial deal but I guess not entirely unexpected in this stage of the market.

It’s a sleep easy hold for me. When I entered at 9c it was based on the anticipated uplift as they begin to fulfil my commercial expectations. Over the last few years they’ve done a bunch of pilots and spent the time ensuring that the product is correctly matched to the consumer. We’re now at the stage where that consumer is happy to pay for the privilege of testing our product for their user base.

While this deal is for 100 customers it’s a client that services 1 in 4 US pregnancies. With them and Mayo Clinic now on the hook in the US, Ramsay in Australia, Hapvida in Brazil and Sheba in Israel it’s starting to look like a transitional year for commercial traction.

The share price will do its thing but the company is delivering as per expectation.